- Tirzepatide (CAS 2023788-19-2) is a high-purity dual GIP/GLP – 1 receptor agonist metabolic API with a synergistic metabolic regulatory mechanism. It simultaneously activates GIP and GLP – 1 receptors, enhancing glucose – dependent insulin secretion, inhibiting glucagon release, reducing food intake and slowing gastric emptying. It shows remarkable efficacy in lowering blood glucose of type 2 diabetes patients and promoting weight loss in overweight/obese people, and also exerts positive effects on improving lipid metabolism and insulin sensitivity. Its lyophilized form ensures stable bioactivity and low impurity content, serving as a reliable active ingredient for metabolic disease pharmaceutical R&D.
- Tailored for pharmaceutical manufacturers and metabolic disease research institutions, this product complies with strict international quality and regulatory standards. It meets the core demand for dual – target metabolic raw materials, supporting the development of formulations for type 2 diabetes and obesity treatment. Its stable peptide structure and lyophilized preparation allow for flexible formulation design such as subcutaneous injection preparations and clinical trial applications.
Tirzepatide (CAS 2023788-19-2)/tirzepatide peptide
$14,000.00
Tirzepatide tirzepatide peptide is a bioactive peptide primarily used for its targeted biological effects in pharmaceutical, cosmetic, and research applications, including tissue repair, anti-aging, and therapeutic development.
Be the first to review “Tirzepatide (CAS 2023788-19-2)/tirzepatide peptide”
Reviews
There are no reviews yet.